Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

AFYX Therapeutics

Request full access

Private biopharmaceutical company providing targeted drug delivery for mucosal diseases

Copenhagen, DenmarkFounded 2013Biotech & Life Sciences

About AFYX Therapeutics

AFYX Therapeutics is a pioneering healthcare startup specializing in the development of innovative mucoadhesive patches for the treatment of mucosal diseases. The company focuses on creating topical patches that adhere to mucosal surfaces, such as the oral cavity and vulvar area, to deliver medication directly to the affected site. This targeted approach aims to improve treatment efficacy while minimizing side effects.

AFYX Therapeutics primarily serves patients suffering from conditions like Vulvar Lichen Sclerosus and oral mucosal diseases. These conditions often require localized treatment, which AFYX's patches are designed to provide. The company operates in the biopharmaceutical market, specifically within the niche of mucosal drug delivery systems.

The business model of AFYX Therapeutics revolves around research and development (R&D) of these specialized patches, followed by clinical trials to ensure their safety and effectiveness. Once the products are proven effective, the company seeks regulatory approval to bring them to market. AFYX makes money by securing funding through convertible loans and investments, as well as through potential future sales of their approved products.

AFYX Therapeutics has already made significant strides, including closing a $13 million convertible loan financing and submitting Investigational New Drug (IND) and Clinical Trial Application (CTA) for Phase 2B studies. The company collaborates with renowned experts and institutions in dermatology and oral health to validate their products.

In summary, AFYX Therapeutics is dedicated to improving the lives of patients with mucosal diseases through innovative, targeted drug delivery systems. Their focus on R&D, clinical validation, and strategic partnerships positions them well in the biopharmaceutical market.

Source: Dealroom company data

At a glance

Status
Operational
Employees
12
Open positions
None listed
Dealroom signal
92.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, Horizon Europe, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
CONVERTIBLE✓Equity / VC Jun 2019 $13M — Sofinnova Investments · Novo Seeds · Lundbeckfonden Emerge —
SERIES A✓Equity / VC May 2017 $18M $71M Lundbeckfonden Emerge · Novo Seeds · Sofinnova Investments ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

AFYX Therapeutics website traffic

Latest recorded traffic for AFYX Therapeutics is 520 monthly website visits, up 73.3% over the last three months. AFYX Therapeutics's team grew 0% over the past year.

Latest monthly visits520 3-month web change+73.3% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

AFYX Therapeutics in the Copenhagen ecosystem

Live from Dealroom

The AFYX Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Lundbeckfonden Emerge
  • Novo Seeds
  • Sofinnova Investments

Other known investors2 additional known investors

  • Lundbeckfonden
  • Novo Holdings
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇩🇰 Denmark90.9%
🇬🇷 Greece9.1%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about AFYX Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See AFYX Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.